In December 2023, the 2023 National Medical Insurance Catalogue was announced, and three new domestic oral drugs in the field of diabetes were selected: dolagliatin tablets, repaglitin phosphate tablets, and ticagliptin hydrobromide tablets.
What are the advantages and characteristics of each of these 3 drugs, let's learn about them separately.
1. Dolagliatin tablets
In early October 2022, it was approved for marketing by the State Food and Drug Administration under the trade name "Huatangning" for patients with type 2 diabetes.
The drug is a new hypoglycemic drug developed by mainland China with complete intellectual property rights, and is the world's first new GKA drug with a new hypoglycemic mode and put into application.
Dolagliatin targets the activation of glucokinase, which is the body's "sensor" of blood glucose, which automatically regulates and keeps blood sugar stable. The original intention of research and development is to target patients with glucokinase, which is either "lacking" or "lazy", and by activating and whipping the "slow cow" method, glucokinase can be effective, so as to achieve the purpose of controlling blood sugar stability in the human body.
Dolagliatin has new tricks in lowering blood sugar, in fact, there are 3 major advantages:
First, when large multinational pharmaceutical companies have successively abandoned the targets of research and development, mainland researchers have risen to the challenge and finally made a breakthrough after ten years of sharpening their swords, and the research blueprint is mainly based on domestic patients, which can stand up to testing.
Second, the efficacy is credible and available, the glycosylated hemoglobin is effectively reduced, the blood glucose is significantly reduced at 2 hours after meals, the response rate and safety are high, there are no serious hypoglycemic events, the drug resistance is low, and the compliance is good.
Third, it is not metabolized by the kidneys, there is no accumulation of kidney metabolites and residual drugs, even if the kidney function is very poor, it can be used, the kidney protection effect is excellent, and there are no cardiovascular problems.
The price of dolagliatin tablets was negotiated from 15 yuan per tablet to 5.39 yuan, a decrease of 64%.
2. Repaglitin phosphate tablets
In June 2023, it was approved for marketing by the State Food and Drug Administration under the trade name "Ruizetang" for patients with type 2 diabetes.
The drug is the first self-developed DPP-4i hypoglycemic drug in mainland China, with DPP-4 as the target, and has as many as 9 invention patents in China, making it a domestic class 1 new drug.
After repagitin phosphate tablets enter the human body, it is hydrolyzed to produce repagretin acid, which can inactivate DPP-4 and reduce and prevent the decomposition of the hormone GLP-1 secreted by insulin-propel, so as to achieve glucose control and hypoglycemia without cardiovascular adverse reactions.
At present, there are a number of DPP-4 inhibitor drugs on the market, and repagliptin phosphate tablets are better than the "main force" sitagliptin in the main indicators, and the toxicity is less and the specificity is higher.
The mechanism of action of repaglatin phosphate tablets is unique, it has less irritation to the stomach and intestines, and does not gain weight, does not cause hypoglycemia, has low side effects, and its hypoglycemic mildness is especially suitable for elderly patients with type 2 diabetes, and studies have also found that it can be used in combination with metformin for better results.
3. Titagliptin hydrobromide tablets
In May 2023, it was approved for marketing by the State Food and Drug Administration under the trade name "Ketangwen" for patients with type 2 diabetes.
The drug is different from the other two domestic self-developed new drugs, it is a generic drug, and it is the first generic drug of ticagliptin on the market in mainland China. The original drug is Tenelia, a DPP-4 inhibitor from Mitsubishi Tanabe Pharmaceutical of Japan, which was launched in Japan in 2012 and in mainland China in 2021.
The hypoglycemic effect of titagliptin hydrobromide tablets is better than that of other DPP-4 inhibitors, such as sitagliptin and linagliptin, which can reduce fasting blood sugar and postprandial blood sugar, improve insulin resistance, and is relatively friendly to the kidneys and cardiovascular.
Tepagliptin hydrobromide tablets entered the medical insurance by bidding, and it is also the first DPP-4 inhibitor in China to successfully bid for medical insurance, with the original drug at 14.5 yuan per tablet, and the generic drug at 3.5 yuan per tablet after successful bidding, a decrease of more than 70%.
Dolagliatin tablets, rerigatin phosphate tablets, and titagliptin hydrobromide tablets, 2 of which are domestic self-developed innovative drugs and 1 is a generic drug, but they all have their own advantages, which are commendable in terms of safety and convenience, and the hypoglycemic effect is mild, which can protect the heart and kidneys, and reduce the risk of cardiovascular events, especially after being included in the medical insurance, the price of dolagliatin tablets and ticagliptin hydrobromide tablets has been greatly reduced, exceeding 60%, which is good news for patients.